{"nctId":"NCT01492686","briefTitle":"Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis","startDateStruct":{"date":"2011-12"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"count":137,"armGroups":[{"label":"Arm 1","type":"EXPERIMENTAL","interventionNames":["Drug: MCI-186","Drug: MCI-186 in open label phase"]},{"label":"Arm 2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: MCI-186 in open label phase"]}],"interventions":[{"name":"MCI-186","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"MCI-186 in open label phase","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients whose conditions are defined as \"definite ALS\"or \"probable ALS\"diagnostic criteria El Escorial and revised Airlie House.\n* Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life.\n* Patients of less than 2 years after the onset of ALS.\n* Patients whose progress of the condition during 12 weeks before administration meet other requirements.\n\nExclusion Criteria:\n\n* Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone.\n* Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception.\n* Patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present.\n* In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks","description":"0=worst; 48=best","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.01","spread":"0.64"},{"groupId":"OG001","value":"-7.5","spread":"0.66"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Death or a Specified State of Disease Progression","description":"Any of \"death, disability of independent ambulation, loss of upper limbs function, tracheotomy, use of respirator, use of tube feeding and loss of useful speech\" was defined as an event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.61","spread":"2.41"},{"groupId":"OG001","value":"-20.4","spread":"2.48"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks","description":"The Modified Norris Scale is a measure of movement disorder for patients with ALS. 0=worst; 102=best","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.91","spread":"1.97"},{"groupId":"OG001","value":"-20.8","spread":"2.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks","description":"The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, Activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. 200=worst; 40=best","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.25","spread":"3.39"},{"groupId":"OG001","value":"26.04","spread":"3.53"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null},{"groupId":"OG001","value":"83.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Drug Reactions","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Laboratory Tests Percentage of Participants With Adverse Events by System Organ Class (SOC) of \"Investigations\" (PT, MedDRA Ver. 17.0)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Abnormal Values in Sensory Examinations","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":69},"commonTop":["Contusion","Constipation","Dysphagia","Nasopharyngitis","Dermatitis contact"]}}}